Cargando…

Screening for inhibitors against SARS-CoV-2 and its variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, generating new variants that pose a threat to global health; therefore, it is imperative to obtain safe and broad-spectrum antivirals against SARS-CoV-2 and its variants. To this end, we screened compounds for their ab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Weijing, Dong, Xiaojing, Chen, Lan, Lei, Xiaobo, Zhou, Zhuo, Guo, Li, Wang, Jianwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Medical Association Publishing House. Published by Elsevier BV. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077799/ https://www.ncbi.nlm.nih.gov/pubmed/35574239 http://dx.doi.org/10.1016/j.bsheal.2022.05.002

Ejemplares similares

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron
por: Su, Jingyi, et al.
Publicado: (2022)

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
por: Xia, Shuai, et al.
Publicado: (2021)

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
por: Xiao, Xia, et al.
Publicado: (2020)

Circular RNA vaccines against SARS-CoV-2 and emerging variants
por: Qu, Liang, et al.
Publicado: (2022)

Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants
por: Ferdous, Nadim, et al.
Publicado: (2021)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Activation and evasion of type I interferon responses by SARS-CoV-2
por: Lei, Xiaobo, et al.
Publicado: (2020)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation
por: Wang, Wenjing, et al.
Publicado: (2021)

Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants
por: Muhammad, Ijaz, et al.
Publicado: (2021)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Ou, Xiuyuan, et al.
Publicado: (2020)

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
por: Acharya, Arpan, et al.
Publicado: (2021)

Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling
por: Mandal, Nabanita, et al.
Publicado: (2023)

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern
por: Xing, Lixiao, et al.
Publicado: (2022)

Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern
por: Boshah, Hattan, et al.
Publicado: (2023)

Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Ou, Xiuyuan, et al.
Publicado: (2021)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection
por: Kothandan, Ram, et al.
Publicado: (2021)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

Entry-inhibitory role of catechins against SARS-CoV-2 and its UK variant
por: Mhatre, Susmit, et al.
Publicado: (2021)

Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
por: Esposito, Francesca, et al.
Publicado: (2023)

SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated
por: Angius, Fabrizio, et al.
Publicado: (2021)

Lessons from SARS-CoV-2 and its variants
por: Qin, Ziwen, et al.
Publicado: (2022)

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
por: Mulgaonkar, Nirmitee, et al.
Publicado: (2023)

Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants
por: Yang, Qiangzhen, et al.
Publicado: (2022)

Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination
por: Zhang, Xiaomei, et al.
Publicado: (2022)

Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry
por: Zhu, Shiyou, et al.
Publicado: (2021)

Mutagenesis and structural studies reveal the basis for the specific binding of SARS-CoV-2 SL3 RNA element with human TIA1 protein
por: Zhang, Dong, et al.
Publicado: (2023)

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
por: Qu, Yuanyuan, et al.
Publicado: (2021)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach
por: Singh, Sanjay Kumar, et al.
Publicado: (2021)

Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
por: Kuo, Chih-Jung, et al.
Publicado: (2021)

Antibody cocktail effective against variants of SARS-CoV-2
por: Liang, Kang-Hao, et al.
Publicado: (2021)

Are the new SARS-CoV-2 variants resistant against the vaccine?
por: Abdalla, Mohnad, et al.
Publicado: (2021)

In vitro activity of cysteamine against SARS-CoV-2 variants
por: Thoene, Jess, et al.
Publicado: (2022)

Genetic Variants and Protective Immunity against SARS-CoV-2
por: Rabaan, Ali A., et al.
Publicado: (2022)

Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors
por: Huang, Li, et al.
Publicado: (2022)

Yeast Based Small Molecule Screen for Inhibitors of SARS-CoV
por: Frieman, Matthew, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9ncpa42os6v4au9pqkat1bf3j5